Search Within

Thoracic Oncology

Formats
  1. Meeting Abstract (1709)
  2. Journal Article (1439)
  3. Review (82)
  4. Editorial (58)
  5. Book Section (35)
  6. Guidelines (25)
  7. Conference Paper (21)
  8. Correspondence (10)
  9. Research Letter (7)
  10. Miscellaneous (6)
  11. Book Whole (2)
Groups
  1. Department of Medicine (3394)
  2. Solid Tumor Oncology Division (3394)
  3. GSK Faculty (1071)
  4. Department of Pathology and Laboratory Medicine (809)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (662)
  6. Human Oncology and Pathogenesis Program (635)

More Groups

People
  1. Mark Kris (872)
  2. Alexander Drilon (637)
  3. Gregory Riely (605)
  4. Charles Rudin (495)
  5. Marc Ladanyi (418)
  6. Matthew Hellmann (412)

More People

Years
  1. 2025 (114)
  2. 2024 (271)
  3. 2023 (273)
  4. 2022 (337)
  5. 2021 (337)
  6. 2020 (258)

More Years

Publications
  1. Journal of Clinical Oncology (703)
  2. Journal of Thoracic Oncology (517)
  3. Annals of Oncology (278)
  4. Clinical Cancer Research (158)
  5. Cancer Research (128)
  6. International Journal of Radiation Oncology, Biology, Physics (89)

More Publications

Publishers
  1. American Society of Clinical Oncology (782)
  2. Elsevier Inc. (738)
  3. American Association for Cancer Research (386)
  4. Oxford University Press (352)
  5. Nature Publishing Group (156)
  6. Elsevier Science, Inc. (79)

More Publishers

Results (3394)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and safety of pembrolizumab (pembro; MK-3475) for patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC) enrolled in KEYNOTE-001
    Meeting Abstract

    Soria, J. C.; Flotten, O.; Horn, L.; Felip, E.; Gandhi, L.; Hui, R.; Hellmann, M.; Leighl, N.; Zhang, J.; Kondic, A.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • Entrectinib (RXDX-101), an oral pan-Trk, ROS1, and ALK inhibitor in patients with advanced solid tumors harboring gene rearrangements
    Meeting Abstract

    Siena, S.; Drilon, A. E.; Ou, I. S. H.; Farago, A. F.; Patel, M.; Bauer, T. M.; Hong, D.; Liu, S. V.; Lee, J.; Patel, R.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC)
    Meeting Abstract

    Pietanza, M. C.; Spigel, D.; Bauer, T. M.; Ready, N. E.; Glisson, B. S.; Morgensztern, D.; Robert, F.; Salgia, R.; Kochendorfer, M.; Patel, M.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • Dose optimization of rociletinib for EGFR mutated NSCLC: Benefit/risk analysis from the TIGER-X trial
    Meeting Abstract

    Soria, J. C.; Goldman, J. W.; Wakelee, H.; Gadgeel, S.; Camidge, D. R.; Solomon, B.; Yu, H.; Oxnard, G. R.; Ou, S. H.; Papadimitrakopoulou, V.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • Rociletinib treatment and outcomes in non-small cell lung cancer (NSCLC) patients with negative central testing for T790M
    Meeting Abstract

    Solomon, B.; Wakelee, H.; Sequist, L. V.; Gadgeel, S.; Soria, J. C.; Goldman, J. W.; Yu, H.; Camidge, D. R.; Papadimitrakopoulou, V.; Matheny, S.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Hellmann, M. D.; Rizvi, N.; Gettinger, S. N.; Goldman, J.; Chow, L. Q.; Juergens, R.; Borghaei, H.; Brahmer, J.; Shen, Y.; Harbison, C. T.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses
    Meeting Abstract

    Gettinger, S. N.; Hellmann, M. D.; Shepherd, F. A.; Antonia, S. J.; Brahmer, J.; Chow, L. Q.; Goldman, J.; Juergens, R.; Borghaei, H.; Ready, N. E.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) safety profile: Summary of findings from trials in patients (pts) with advanced squamous (SQ) non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Gettinger, S. N.; Horn, L.; Ramalingam, S. S.; Spigel, D. R.; Paz-Ares, L.; Paik, P.; Reck, M.; Reckamp, K.; Mazieres, J.; Stinchcombe, T.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • Efficacy of rociletinib (co-1686) in EGFR-mutant non-small cell lung cancer (NSCLC) patients (pts) assessed with a plasma EGFR test
    Meeting Abstract

    Gadgeel, S.; Soria, J. C.; Goldman, J. W.; Wakelee, H.; Camidge, D. R.; Yu, H.; Varga, A.; Solomon, B.; Oxnard, G. R.; Ou, S. H.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • A phase 1b study to evaluate the safety and antitumor activity of MEDI4736 in combination with tremelimumab in patients with advanced NSCLC
    Meeting Abstract

    Goldberg, S. B.; Balmanoukian, A.; Chaft, J.; Rizvi, N.; Sanborn, R. E.; Rebelatto, M. C.; Narwal, R.; Robbins, P. B.; Gu, Y.; Karakunnel, J. J.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save